Incretin-based Therapies

Mechanism

Related News

AbbVie Reports Positive Phase 1 Results for ABBV-295 Obesity Treatment

Mar 09, 2026

AbbVie announced positive Phase 1 results for ABBV-295, a long-acting amylin analog for obesity treatment, showing clinically meaningful weight loss with favorable tolerability across all dose levels tested.

Eli Lilly's Orforglipron Shows Greater Weight Loss Than Oral Semaglutide in Phase 3 Trial

Feb 26, 2026

Eli Lilly's oral GLP-1 drug orforglipron demonstrated 6-8% weight loss in type 2 diabetes patients compared to 4-5% with oral semaglutide in a phase 3 trial, though discontinuation rates were higher due to gastrointestinal side effects.